YOLFTbeta
Sansure Biotech Inc

Sansure Biotech Inc

688289 · SHG · Healthcare / Medical Instruments & Supplies

14.98CNY-0.40 (-2.60%)

Price History

Full chart

Market Stats

Previous Close15.38
Open15.39
Day Range14.97 – 15.53
52-Week Range13.40 – 22.51
Volume3.46M
Market Cap9.61B
P/E (TTM)72.70
Forward P/E0.00
EPS0.23
Dividend Yield3.13%
Beta0.49
50-Day Avg15.92
200-Day Avg17.27

About

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; and diagnostic kits for monkeypox, epstein-barr virus, and human cytomegalovirus DNA, as well as rapid antigen tests. The company provides nucleic acid extraction or purification kits, multi-type sample DNA/RNA extraction-purification kits, and sample release reagents; sample storage reagents for SARS-CoV-2; extraction instruments and systems; and PCR instruments comprising real-time quantitative thermal cyclers, portable molecule workstations, and real-time PCR systems. In addition, it engages in the research and development, production, and sale of drugs; procurement and sale of raw materials; manufacture of instruments; manufacture and sale of electronic equipment; trading; investment consulting; medical research and experimental development; and internet sales, as well as offers third-party medical testing and biotechnology development services. The company was founded in 2008 and is headquartered in Changsha, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Lizhong Dai
  • Employees2.06K
  • HeadquartersNo. 680, Lusong Road, Changsha, China, 410205, China
  • Websitehttps://www.sansure.com.cn

Leadership

  • Mr. Lizhong DaiChairman of the Board & GM · b. 1968
  • Mr. Zhu PengCFO, Deputy GM & Director · b. 1975
  • Mr. Haixiao WangDeputy GM & Director · b. 1978
  • Mr. Kang WuDeputy GM & Director · b. 1985
  • Ms. Xiao Mei RenEmployee Director · b. 1987
  • Mr. Qiang HuangSecretary · b. 1982
  • Mr. Zhongping DengDeputy General Manager · b. 1977
  • Ms. Xiaoyan XiongDeputy General Manager · b. 1983
  • Mr. De Yong TanDeputy General Manager · b. 1987
  • Dr. Keya ZhangCore Technical Personnel · b. 1985

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue224.60M303.45M365.39M4.76B4.51B6.45B1.01B1.46B1.65B
Growth (%)-+35.11%+20.41%+1203.53%-5.22%+42.88%-84.39%+44.78%+13.04%
Cost of Revenue113.16M126.83M128.43M971.99M1.28B2.91B280.96M279.71M397.48M
Gross Profit111.44M176.61M236.96M3.79B3.23B3.54B726.15M1.18B1.65B
Gross Margin49.62%58.20%64.85%79.59%71.58%54.85%72.10%80.82%100.00%
Operating Expense139.17M164.91M189.44M704.94M609.80M1.20B298.69M900.58M1.45B
Operating Income-27.73M11.70M47.52M3.09B2.62B2.34B427.46M277.78M202.43M
Operating Margin-12.35%3.86%13.00%64.79%58.07%36.27%42.44%19.05%12.28%
EBITDA38.39M30.89M66.72M3.10B2.66B2.39B516.89M419.64M315.98M
EBITDA Margin17.09%10.18%18.26%65.04%59.01%37.12%51.32%28.78%19.17%
Net Income-10.65M6.76M39.48M2.62B2.24B1.94B363.72M275.60M198.15M
Net Income Margin-4.74%2.23%10.80%54.94%49.68%30.03%36.12%18.90%12.02%
R&D27.64M35.68M38.95M82.77M187.50M331.83M196.28M277.69M229.11M
R&D as % of Total Revenue12.31%11.76%10.66%1.74%4.15%5.14%19.49%19.04%13.90%
Interest Expense16.35M93.20K622.24K992.74K1.83M3.03M5.53M18.40M24.13M
Interest Expense % of Total Revenue7.28%0.03%0.17%0.02%0.04%0.05%0.55%1.26%1.46%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets565.61M552.04M642.47M5.45B7.09B9.17B8.45B8.60B9.53B
Total Liabilities186.62M155.76M84.99M708.95M709.03M1.66B1.03B1.26B-7.22B
Total Equity378.99M396.29M557.48M4.75B6.37B7.50B7.20B7.24B7.22B
Cash39.91M127.01M99.17M2.59B2.64B3.21B4.23B4.59B3.97B
Total Debt---55.00M14.90M27.86M27.21M417.57M-
Net Debt-39.91M-127.01M-99.17M-2.54B-2.62B-3.18B-4.21B-4.17B-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-61.44M10.07M22.41M2.64B1.88B2.56B112.82M274.45M183.96M
Investing Cash Flow-65.75M77.52M-94.60M-1.72B-1.11B-1.17B1.40B-101.92M-
Financing Cash Flow147.33M-44.39M1.61B-688.59M-915.95M-529.11M132.49M-
Capital Expenditure20.69M32.90M34.14M108.67M372.86M558.83M391.35M421.10M369.77M
Free Cash Flow-82.13M-22.84M-11.74M2.53B1.50B2.00B-347.81M-146.66M-185.81M
Dividends Paid5.58M--300.00M449.31M647.24M400.07M268.40M333.68M
FCF to OCF133.67%-226.86%-52.38%95.89%80.14%78.16%-308.28%-53.44%-101.00%
Dividend Paid to FCF-6.80%--11.84%29.87%32.36%-115.03%-183.01%-179.59%

Earnings

Report DateOct 30, 2020Feb 25, 2021Apr 27, 2021Aug 29, 2021Oct 25, 2021Feb 24, 2022Apr 30, 2022Aug 29, 2022Oct 20, 2022Feb 27, 2023Apr 25, 2023Aug 16, 2023
EPS Estimate------------
EPS Actual1.321.021.050.841.080.821.110.810.810.580.100.05
Surprise------------
TimingPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hours

Key Statistics & Ratios

Market Cap9.61B
Enterprise Value7.23B
Trailing P/E72.70
Forward P/E0.00
Price / Sales5.98
Price / Book1.36
EPS0.23
Book Value12.26
Revenue (TTM)1.61B
Gross Profit (TTM)1.17B
EBITDA261.39M
Profit Margin8.35%
Operating Margin-3.12%
Return on Equity1.28%
Return on Assets0.24%
Shares Outstanding574.94M
Shares Float291.80M
Beta0.49
Dividend Yield3.13%
Dividend Rate0.52
Payout Ratio227.39%

Dividends

20262×
0.27Oct 15, 20260.26Jun 22, 2026
20252×
0.26Sep 23, 20250.28Jun 11, 2025
20242×
0.25Sep 26, 20240.20Jun 11, 2024
20232×
0.26Dec 11, 20230.44May 29, 2023
20222×
0.86Nov 29, 20220.38Jun 1, 2022
20212×
0.51Dec 3, 20210.25May 7, 2021
20201×
0.51Dec 3, 2020

Stock Splits

  • Jun 1, 20221.48:1